Heinz Ludwig, MD, completed his medical studies at the University of Vienna, where he earned a degree in internal medicine. He later obtained degrees in hemato-oncology, transfusion medicine and human genetics. Prof. Ludwig has previously been the head of ESMO and is part of the director’s board of ASCO. He is also part of the board of International Myeloma Foundation, of the National Health Council of Vienna, and president of the Austrian Forum Against Cancer. Dr Ludwig is also interested in patients interests and rights. He is responsible for the publishment of an international charter of cancer patient’s rights.
Speaking on the role of signal transduction molecule inhibitors in myeloma cell lines and carfilzomib-combination regimens
Dr Ludwig is interested in hematology and medical oncology, particularly in the field of multiple myeloma. He is currently studying the role of certain signal transduction molecule inhibitors in myeloma cell lines, and is running academic trials with ixazomib and others with carfilzomib-combination regimens. He also participates in several international studies.